Your session is about to expire
← Back to Search
AC176 for Prostate Cancer
Study Summary
This trial is testing a new drug, AC176, on people with prostate cancer that has spread and is resistant to hormone therapy. The goal is to see if it is safe and effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't taken any cancer treatment drugs or participated in a clinical study for at least 4 weeks.I need steroids for my brain metastases symptoms.My heart's pumping ability is below normal.I have undergone surgical or medical castration.I have conditions or take medications that could affect my heart's rhythm.My cancer has worsened after two treatments, including one like abiraterone.I don't have severe side effects from past treatments, except for possible hair loss or mild nerve issues.I can swallow pills and don't have major stomach or bowel issues affecting medication absorption.My advanced cancer is confirmed by scans or rising PSA levels.I am fully active or can carry out light work.I have been diagnosed with moderate to severe heart failure.My prostate cancer has worsened despite standard treatments.I haven't had radiation therapy in the last 4 weeks, except for pain relief from bone metastasis.I haven't had major surgery in the last 4 weeks.I am a man aged 18 or older.I have undergone more than 2 chemotherapy treatments.I plan to try for a child during or within 3 months after the study.
- Group 1: AC176 Dose Escalation as Single Agent
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has AC176 received regulatory clearance from the Food and Drug Administration?
"The safety of AC176 has been given a provisional score of 1, due to the fact that it is presently undergoing Phase 1 trials. This signifies there are limited clinical data affirming its efficacy and security profile."
What is the population size of this scientific investigation?
"Indeed, clinicaltrials.gov proclaims that this medical trial is now recruiting participants. The study was originally shared on March 16th 2022 and recently updated on April 6th 2022. 36 individuals need to be recruited from 4 distinct sites."
Have recruitment efforts for this trial commenced?
"As indicated on clinicaltrials.gov, this research project is currently recruiting participants and has been since March 16th 2022 when it was initially posted, with the last updates occurring April 6th of the same year."
Share this study with friends
Copy Link
Messenger